біотехнологія

Possibility of Obtaining Hyaluronic Acid from Cyanobacteria

The results of studies on the possible producing valuable substances from cyanobacterial biomass are presented. It is shown that the main source of hyaluronic acid is the cyanobacteria from surface waters known as Microcystis aeruginosa and cyanobacterial associations of actinomycetes. The possibility of hyaluronic acid extraction has been experimentally proven. The dynamics of its quantitative characteristics were determined.

Lactic Acid: Industrial Synthesis, Microorganisms-Producers and Substrates: A Review

The article contains comprehensive information on groups of bacteria producing lactic acid, which have high metabolic activity and can be used in industrial production. In addition, an overview of the most common fermentation methods (batch, continuous, multiple), as well as cheap carbon sources: starch and cellulose-containing, industrial and food waste is provided.

FORMATION OF EXPERIENCE AGAINST THE CHALLENGES OF VIRAL INFECTION THROUGH THE USE OF STUDENTS KNOWLEDGE OF BIOSAFY TECHNOLOGIES, part 2

New challenges and the state of development of COVID-19 in connection with the spread of new strains of SARS-CoV-2 have been analyzed. Experience and knowledge in working with new means of protection of different types of vaccines are studied: both classic, based on inactivated virus or its fragment, and the new generation – with vector and genetic mRNA vaccines, as well as effective antiviral drugs. Biorisks and compliance with biosafety principles have been studied.

FORMATION OF EXPERIENCE AGAINST THE CHALLENGES OF VIRAL INFECTION THROUGH THE USE OF STUDENTS KNOWLEDGE OF BIOSAFY TECHNOLOGIES, part 1

New challenges and the state of development of COVID-19 in connection with the spread of new strains of SARS-CoV-2 have been analyzed. Experience and knowledge in working with new means of protection of different types of vaccines are studied: both classic, based on inactivated virus or its fragment, and the new generation - with vector and genetic mRNA vaccines, as well as effective antiviral drugs. Biorisks and compliance with biosafety principles have been studied.